The pharmaceutical sector comprises companies involved in manufacturing active pharmaceutical ingredients (APIs), formulations, biologics, speciality medicines, and contract manufacturing services. Growth in the sector is supported by increasing healthcare demand, exports, research and development, and expansion into regulated markets.
Analysing stocks based on 5‑year CAGR helps identify companies that have delivered sustained long‑term performance. Based on available data for July 2026, the following pharma stocks stand out on this metric.
| Name | 5Y CAGR (%) | Market Cap (₹ crore) | PE Ratio | Return on Equity (%) | PB Ratio |
| Neuland Laboratories | 57.13 | 24,431.96 | 67.12 | 21.42 | 13.03 |
| Wockhardt | 32.06 | 31,843.59 | 149.50 | 4.29 | 6.03 |
| Glenmark Pharmaceuticals | 29.75 | 63,040.84 | 46.29 | 12.54 | 7.12 |
| Torrent Pharmaceuticals | 27.25 | 194,854.85 | 90.07 | 17.19 | 11.08 |
| Marksans Pharma | 25.88 | 11,707.49 | 28.02 | 16.64 | 4.70 |
| Caplin Point Laboratories | 23.26 | 19,130.62 | 29.83 | 20.50 | 6.63 |
| Laurus Labs | 23.14 | 98,131.51 | 110.41 | 17.72 | 18.07 |
| Sun Pharmaceutical Industries | 20.80 | 477,587.63 | 41.60 | 14.68 | 5.69 |
| AstraZeneca Pharma India | 19.17 | 20,250.00 | 107.99 | 22.82 | 23.20 |
| Ajanta Pharma | 17.79 | 43,300.80 | 41.00 | 25.39 | 9.56 |
Note: Data as of July 6, 2026
Neuland Laboratories specialises in active pharmaceutical ingredients, custom manufacturing, and contract development and manufacturing services. The company supplies products to pharmaceutical firms across regulated and emerging markets, with a focus on complex and high‑value molecules.
It has expanded its CDMO operations while strengthening manufacturing and research capabilities. Business growth is linked to increasing global demand for outsourced pharmaceutical manufacturing and speciality APIs.
Wockhardt operates in pharmaceuticals and biotechnology, with businesses spanning formulations, APIs, vaccines, and biologics. The company has a presence across India, the US, the UK, Ireland, and other international markets.
It continues to develop novel antibiotics and speciality pharmaceutical products through research‑driven initiatives. Performance is influenced by product launches, regulatory approvals, export demand, and research outcomes.
Glenmark Pharmaceuticals is engaged in branded formulations, generic medicines, speciality therapies, and API manufacturing. The company has established a presence in therapeutic areas such as respiratory care, dermatology, oncology, and cardiovascular treatments.
It continues to invest in innovation and expansion across global markets. Growth is driven by new product launches, speciality medicine development, and increasing demand for pharmaceutical products.
Torrent Pharmaceuticals operates in chronic therapy segments including cardiovascular, central nervous system, gastrointestinal, and diabetes care. The company has a presence in more than 40 countries and maintains manufacturing and research facilities serving global markets.
It continues to strengthen its portfolio through acquisitions, product launches, and regulated market expansion. Business performance is supported by healthcare demand, exports, and a diversified product portfolio.
Marksans Pharma develops and manufactures pharmaceutical formulations across multiple therapeutic categories. The company has a significant presence in regulated markets including the United Kingdom, the United States, and Australia.
It continues to expand its manufacturing capabilities and product portfolio through export‑focused growth. Performance depends on product approvals, regulatory clearances, and demand across international healthcare markets.
Caplin Point Laboratories manufactures pharmaceutical formulations and active pharmaceutical ingredients with a strong focus on Latin America, Africa, and the United States. The company is known for its branded generic business and growing injectable product portfolio.
It continues to invest in regulated markets and manufacturing expansion. Business growth is driven by exports, product diversification, and demand for affordable healthcare solutions.
Laurus Labs operates across APIs, formulations, biotechnology, speciality chemicals, and contract manufacturing services. The company supplies products to global pharmaceutical players and has expanded beyond its antiviral portfolio.
It has strengthened CDMO and biologics capabilities to cater to rising outsourcing requirements. Growth is supported by manufacturing expansion, innovation, and increasing demand for complex pharmaceutical products.
Sun Pharmaceutical Industries is India's largest pharmaceutical company with operations spanning speciality medicines, branded generics, APIs, biologics, and over‑the‑counter products. The company has a presence in more than 100 countries and continues to strengthen its speciality business through acquisitions and research investments.
Its diversified product portfolio supports revenue across multiple therapeutic areas. Business performance is influenced by product launches, regulatory approvals, and global healthcare demand.
AstraZeneca Pharma India markets prescription medicines across oncology, cardiovascular, renal, respiratory, and rare disease therapies. The company benefits from access to innovative products developed by its global parent organisation.
It continues to introduce new therapies in India following regulatory approvals and expanding healthcare requirements. Growth is supported by increasing adoption of speciality medicines and demand for advanced treatment options.
Ajanta Pharma develops and markets branded generics across therapeutic areas such as ophthalmology, dermatology, cardiology, and pain management. The company has a strong presence in India as well as emerging and regulated international markets.
It continues to invest in research, manufacturing capacity, and new product development. Business growth is supported by healthcare demand, export opportunities, and market expansion initiatives.
Read More: Best Gold Stocks in July 2026 Based on 5‑Year CAGR.
Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.
The pharma stocks featured in this list represent a mix of API manufacturers, CDMO providers, speciality drug companies, and diversified pharmaceutical businesses. Their long‑term performance has been influenced by exports, product innovation, research investments, and expansion into regulated markets.
Financial metrics and business models vary across companies, reflecting different positions within the pharmaceutical value chain. As of July 2026, these stocks highlight long‑term growth trends across India's pharmaceutical sector.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 6, 2026, 11:58 AM IST
Akshay Shivalkar
Akshay Shivalkar is a financial content specialist who strategises and creates SEO-optimised content on the stock market, mutual funds, and other investment products. With experience in fintech and mutual funds, he simplifies complex financial concepts to help investors make informed decisions through his writing.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
